Current Issue February 2012, Vol. 48, No. 3

Issue Highlights

Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991
January 2012 (Vol. 48 | No. 2 | Pages 218-225)
Alexander M.M. Eggermont, Stefan Suciu, Alessandro Testori, Wim H. Kruit, Jeremy Marsden, Cornelis J. Punt, Mario Santinami, François Salès, Dirk Schadendorf, Poulam Patel, Reinhard Dummer, Caroline Robert, Ulrich Keilholz, Antoine Yver, Alan Spatz
Targeted agents: How to select the winners in preclinical and early clinical studies?
January 2012 (Vol. 48 | No. 2 | Pages 170-178)
Rachel Goodwin, Giuseppe Giaccone, Hilary Calvert, Marinus Lobbezoo, Elizabeth A. Eisenhauer
The efficacy of zoledronic acid in breast cancer adjuvant therapy: A meta-analysis of randomised controlled trials
January 2012 (Vol. 48 | No. 2 | Pages 187-195)
Tingting Yan, Wenjin Yin, Qiong Zhou, Liheng Zhou, Yiwei Jiang, Yueyao Du, Zhimin Shao, Jinsong Lu

EJC News Focus

WATCH VIDEO

The combination of targeted agents in hormone-sensitive breast cancer may be the way ahead; results from the CLEOPATRA and BOLERO-2 trials, presented at the recent San Antonio Breast Cancer Symposium (Dec 6-10, 2011), suggest that some combinations may dramatically increase progression-free survival.

Also at the meeting, several studies reported on the role of bisphosphonates in the adjuvant setting, which may resolve previous confusion about which women will benefit.

In this month's EJC News Focus, Rob Coleman (University of Sheffield, UK), who was at the meeting, discusses the implications of the new data with Helen Saul.

Stop and go strategy for opioid switching requires flexibility
06 February 2012
Sebastiano Mercadante
I read with interest the paper published by Moksnes et al. This is the first controlled trial regarding opioid switching and authors should be complimented for giving such evidence-based information. ...
Identification of Familial Adenomatous Polyposis carriers among children with desmoid tumours
06 February 2012
Anna A. Kattentidt-Mouravieva, Ina R.R. Geurts-Giele, Ronald R. de Krijger, Max M. van Noesel, Cees P. van de Ven, Ans M.W. van den Ouweland, Joan N.R. Kromosoeto, Winand N.M. Dinjens, Hendrikus J. Dubbink, Ron Smits, Anja Wagner
Abstract: Objective: Desmoid tumours are rare mesenchymal tumours with unpredictable progression and high recurrence risk. They can occur sporadically or in association with Familial Adenomatous Polyp...
Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer
06 February 2012
Javier Rodríguez, Ruth Zarate, Eva Bandres, Valentina Boni, Amaia Hernández, Jesus Javier Sola, Beatriz Honorato, Nerea Bitarte, Jesus García-Foncillas
Abstract: Background: The immunoglobulin G1 (IgG1) monoclonal antibody (MoAb) Cetuximab is active in metastatic colorectal cancer (mCRC) as first or subsequent lines of therapy. Efficacy seems restric...
Treatment strategies for patients with stage IV rectal cancer: A report from the Swedish Rectal Cancer Registry
06 February 2012
M. Hosseinali Khani, L. Påhlman, K. Smedh
Abstract: Background: The optimal treatment strategy for patients with stage IV rectal cancer is unclear. The aim of the present study was to describe trends and compare the different treatment strate...
Reply to Professor Mercadante: Stop and go strategy for opioid switching requires flexibility
03 February 2012
Kristin Moksnes
To the Editor: We are grateful for the interest and response from Mercadante. This study was a randomized, phase II study, and we agree that there were obvious limitations, as discussed in the article...

View More Articles in Press...

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
January 2011 (Vol. 47 | No. 1 | Pages 8-32)
M.S. Aapro, J. Bohlius, D.A. Cameron, Lissandra Dal Lago, J. Peter Donnelly, N. Kearney, G.H. Lyman, R. Pettengell, V.C. Tjan-Heijnen, J. Walewski, Damien C. Weber, C. Zielinski
A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer
June 2011 (Vol. 47 | No. 9 | Pages 1343-1354)
Barbara-Ann Adelstein, Timothy A. Dobbins, Carole A. Harris, Ian C. Marschner, Robyn L. Ward
New drugs in melanoma: It’s a whole new world
September 2011 (Vol. 47 | No. 14 | Pages 2150-2157)
Alexander M.M. Eggermont, Caroline Robert
Preoperative MRI and surgical management in patients with nonpalpable breast cancer: The MONET – Randomised controlled trial
April 2011 (Vol. 47 | No. 6 | Pages 879-886)
N.H.G.M. Peters, S. van Esser, M.A.A.J. van den Bosch, R.K. Storm, P.W. Plaisier, T. van Dalen, S.C.E. Diepstraten, T. Weits, P.J. Westenend, G. Stapper, M.A. Fernandez-Gallardo, I.H.M. Borel Rinkes, R. van Hillegersberg, W.P.Th.M. Mali, P.H.M. Peeters
Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment
November 2011 (Vol. 47 | No. 17 | Pages 2603-2606)
A. Becker, L. Crombag, D.A.M. Heideman, F.B. Thunnissen, A.W. van Wijk, P.E. Postmus, E.F. Smit

Most Read lists are compiled every quarter.

On the Cover

New Issue Alert

Free Trial Issue

Visit EJC Supplements

Read EJC News

EJC EUROFILE: A second chance to influence the Clinical Trials Directive

EJC INTERVIEW: Elderly breast cancer patients 'risk treatment discrimination'

New: Hormone Receptor Positive Breast Cancer Resource Centre

For all the latest research on Hormone Receptor Positive Breast Cancer, including original research articles and video interviews with leading researchers, visit our new resource centre at www.ejcancer-breast.com, edited by Professor Robert E. Coleman.

Access this journal onSciVerse ScienceDirect

EJC iPad app launch video - September 2011

EJC iPad App is now available to our readers. Download from iTunes now!

About the Journal

European Journal of Cancer is an international comprehensive oncology journal that publishes original research, editorial comments, review articles and news on experimental oncology, clinical oncology (medical, paediatric, radiation, surgical), and on cancer epidemiology and prevention.

More